Clear Harbor Asset Management LLC Purchases 2,293 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Clear Harbor Asset Management LLC boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 57.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,262 shares of the medical research company’s stock after acquiring an additional 2,293 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in IQVIA were worth $1,231,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. Capital Performance Advisors LLP acquired a new position in shares of IQVIA in the third quarter worth approximately $27,000. Park Place Capital Corp acquired a new position in shares of IQVIA in the 3rd quarter worth approximately $28,000. Avior Wealth Management LLC boosted its stake in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. increased its position in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after buying an additional 196 shares during the period. Finally, UMB Bank n.a. raised its stake in IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after buying an additional 99 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Wednesday, December 11th. The Goldman Sachs Group decreased their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Redburn Atlantic initiated coverage on IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price target on the stock. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Finally, TD Cowen dropped their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Stock Up 4.0 %

IQV opened at $205.23 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company’s 50-day moving average is $199.69 and its 200 day moving average is $221.32. The firm has a market capitalization of $37.25 billion, a P/E ratio of 26.93, a PEG ratio of 2.01 and a beta of 1.48.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.